OVERVIEW
Spinal muscular atrophy (SMA) is an inherited disorder caused by homozygous deletions or variants in the SMN1 gene. As a consequence of absent or low levels of SMN1 protein, the motor neurons in spinal cord degenerate, resulting in atrophy of the voluntary muscles of the limbs and trunk. Nusinersen is a synthetic antisense oligonucleotide designed to bind to a specific sequence in exon 7 of the SMN2 transcript causing the inclusion of exon 7 in the SMN2 transcript, leading to production of full length functional SMN2 protein, which is very similar to SMN1.

MEDICAL CRITERIA
BlueCHiP for Medicare and Commercial
Nusinersen may be considered medically necessary for patients with infantile-onset or type I spinal muscular atrophy with a documented genetic diagnosis of spinal muscular atrophy.

PRIOR AUTHORIZATION
Prior authorization is required for BlueCHiP for Medicare and recommended for Commercial Products

POLICY STATEMENT
Nusinersen may be considered medically necessary for patients with infantile-onset or type I spinal muscular atrophy with a documented genetic diagnosis of spinal muscular atrophy.

Note: The recommended dosage is 12 mg (5 mL) administered intrathecally. Treatment is initiated with 4 loading doses; the first 3 loading doses should be administered at 14-day intervals while the fourth loading dose is administered 30 days after the third loading dose. Subsequent maintenance doses should be administered once every 4 months thereafter.

Nusinersen is considered not medically for patients with type 0, II, III, and IV spinal muscular atrophy as the evidence is insufficient to determine the effects of the technology on health outcomes.

Authorization period will be for 1 year.
Renewal Criteria
Spinraza (nusinersen) will be approved for continued use when ALL of the following are met:
1. The patient was previously approved
   AND
   a. The prescriber has provided documentation indicating the patient has had disease stabilization or clinical improvement in the symptoms* of SMA (*e.g. motor function, limb and trunk weakness, hypotonia and impaired head control, difficulty breathing, swallowing, feeding, and handling secretions etc)
   AND
   b. The patient does not have any FDA labeled contraindications to therapy with the requested agent
   AND
   c. The requested agent is prescribed by a prescriber (e.g. neurologist, geneticist) that specializes in the diagnosis and management of SMA or in consultation with a prescriber that specializes in the diagnosis and management of SMA
   AND
   d. The requested dose is within FDA approved labeling
**COVERAGE**
Benefits may vary between groups and contracts. Please refer to the appropriate Benefit Booklet, Evidence of Coverage or Subscriber Agreement for applicable not medically necessary services.

**BACKGROUND**
Spinal Muscular Atrophy
Spinal muscular atrophy (SMA) is a rare autosomal recessive genetic disorder caused by homozygous deletions or variants in the SMN1 gene on chromosome 5. This gene is responsible for producing the “survival of motor neuron” protein (SMN1). As a consequence of absent or low levels of SMN1, the motoneurons in the spinal cord degenerate, resulting in atrophy of the voluntary muscles of the limbs and trunk. During early development, these muscles are necessary for crawling, walking, sitting up, and head control. The more severe types of SMA can also affect muscles involved in feeding, swallowing, and breathing. The exact role of the SMN protein in motoneurons has not been completely elucidated and levels of the SMN protein required for optimal functioning are unknown. SMN2 is a nearly identical modifying gene capable of producing nearly identical compensatory SMN2 protein. However, 70% to 90% of the transcripts produced from the SMN2 gene produce a truncated protein that is defective and unstable due to lack of exon 7.
Further, humans exhibit variability (range, 0–6) in the number of copies of the SMN2 gene and copy number is inversely proportional to severity of disease. These factors in tandem lead to wide variability in disease severity.

SMA is classified into 4 main categories (with additional subcategories) based on the age at the onset of symptoms. Generally, early onset of disease directly correlates to severity of symptom and rate of disease progression. There is no exact marker to classify these categories, and they are not well-distinguished by ICD-10-CM code.

- **Type 0:** The most severe form of SMA, symptoms can often be seen in the later stages of pregnancy. Fetal movements are less than expected and, after birth, the infant will have little ability to move and may not be able to breathe and swallow independently. Death occurs before the age of 6 months.
- **Type I** (also called infantile SMA or Werdnig-Hoffman disease and subcategorized as IA, IB and IC): Onset within 6 months of birth and symptoms progress rapidly, and most infants die before 1 year of age from respiratory failure. About 60% of patients with SMA constitute of this phenotype.
- **Type II** (also called intermediate SMA or Dubowitz disease): Onset within 6 to 18 months with a less severe progression. Typically, a child can sit independently if positioned, but is unable to walk. More than 70% of patients live beyond 25 years of age with adequate supportive care.
- **Type III** (also called Kugelberg-Welander disease and subcategorized as IIIA and IIIB): Onset after 18 months of age. Lifespan is not affected, with wide-ranging reduction in muscle strength with a chronic course. The outcome depends primarily on the severity of muscle weakness at presentation rather than age of onset, but earlier onset tends to correlate with greater weakness.
- **Type IV** (also called adult-onset SMA): Usually presents in the third decade of life and is otherwise similar to SMA type III.

**Infantile-Onset or Type I SMA**
For individuals who have type I (infantile-onset) SMA (symptomatic or presymptomatic) who receive nusinersen, the evidence includes 2 randomized, double-blind, controlled trial (results not yet reported for one) and 1 single-arm open-label study. Relevant outcomes are overall survival, change in disease status, morbid events, functional outcomes, health status measures, quality of life, and treatment-related mortality and morbidity. Trial results in symptomatic patients has shown clinically meaningful improvement in motor milestones as well as event-free survival, which exceeded those seen in the control group, with an acceptable safety profile. The proportion of patients, who met the primary end point responder definition of achieving motor milestones, was 40% in the nusinersen arm compared to 0 in the sham-controlled arm. Further, the hazard ratio for event-free survival was 0.53 in favor of nusinersen versus sham controlled. It is notable, however, that most nusinersen-treated subjects did not achieve the primary end point motor milestone response. Given the limited data on durability of response, long-term safety, and lack of efficacy in substantial
number of patients, continued risk-benefit assessment of long-term treatment with nusinersen is necessary. The open-label uncontrolled trial in presymptomatic infantile-onset SMA patients found a benefit of early treatment with nusinersen. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

**Type II and III SMA**

For individuals who have type I or II SMA who receive nusinersen, the evidence includes 4 single-arm studies and 1 double-blind, randomized controlled trial. Relevant outcomes are overall survival, change in disease status, morbid events, functional outcomes, health status measures, quality of life, and treatment-related mortality and morbidity. Efficacy findings from single-arm studies of type II and III SMA are difficult to interpret because these trials used a wide range of nusinersen doses and lacked control arms. Results of the confirmatory phase 3 CHERISH trial are not yet available. The evidence is insufficient to determine the effects of the technology on health outcomes.

**Type 0 or IV SMA**

For individuals who have type 0 SMA or type IV SMA who receive nusinersen, no studies were identified. Relevant outcomes are change in disease status, morbid events, functional outcomes, health status measures, quality of life, and treatment-related mortality and morbidity. The evidence is insufficient to determine the effects of technology on health outcomes.

**Regulatory Status**

In December 23, 2016, Spinraza™ (nusinersen; Biogen) was approved by the U.S. Food and Drug Administration (FDA) for treatment of pediatric and adult patients with spinal muscular atrophy.

**CODING**

For Claims filed with with date of service prior to 7/1/2017
There is no specific HCPCS code, claims must be filed with an unlisted code such as J3490 and the NDC number

For claims filed with date of services 7/1/2017 and after
C9489 Injection, nusinersen, 0.1 mg

For claims filed with date of services 1/1/2018 and after
J2326 Injection, nusinersen, 0.1 mg

**RELATED POLICIES**
none

**PUBLISHED**
Provider Update May 2017

**REFERENCES:**


